You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study

Citation Tools

Article menu
Download PDFPDF
Oral Presentations
Abstract session: Developments in the treatment of RA
OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Genovese M, Kremer J, Zamani O, et al
OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study
Annals of the Rheumatic Diseases 2015;74:75-76.